BSTRACT Background: Osteocalcin has been related to insulin secretion in experimental models. Few prospective studies have evaluated the association between circulating osteocalcin concentrations and insulin secretion and sensitivity in humans. Objective: The objective was to examine cross-sectional and longitudinal associations between circulating forms of osteocalcin and insulin secretion and sensitivity in elderly men at high cardiovascular risk. Design: We examined cross-sectional and longitudinal associations between serum measurements of total osteocalcin and undercarboxylated osteocalcin (ucOC) with fasting glucose, fasting insulin, HOMA-IR, and HOMA b cell function (HOMA-BCF) in 79 elderly men. We also examined the association between 2-y changes in osteocalcin and changes in fasting glucose, insulin, HOMA-IR, and HOMA-BCF. Results: In an adjusted multivariable linear regression analysis, increases in serum osteocalcin were significantly associated with an increase in HOMA-BCF (b coefficient: 2.87; 95% CI: 0.23, 5.52; P = 0.033), and changes in ucOC were linked to a decrease in HOMA-IR (b coefficient: 20.31; 95% CI: 20.60, 0.03; P = 0.032). Moreover, in subjects not taking oral antidiabetic drugs, baseline osteocalcin concentrations were positively associated with higher fasting insulin concentrations and HOMA-BCF even after adjustment for BMI, physical activity, intervention group, presence of type 2 diabetes mellitus, and baseline values of each dependent variable. Conclusions: Changes in serum osteocalcin and ucOC are associated with an improvement in insulin secretion and sensitivity, which suggests a possible role of bone in the development of type 2 diabetes. This trial is registered at clinicaltrials.gov as ISRCTN35739639.
INTRODUCTION
A growing body of evidence supports the role of the skeleton as an endocrine organ, which establishes a cross-talk with energy, glucose, and fat metabolism (1) . It has been proposed that there is a direct link between adipose tissue and bone remodeling via leptin (2) . Insulin can also influence bone metabolism by stimulating osteoblastic cell differentiation, which leads to osteoblastogenesis and activates insulin-like growth factor 1 (1) (2) (3) (4) . Recently, osteocalcin-an abundant noncollagenous, vitamin Kdependent protein in bone-has also appeared to be involved in energy metabolism, adiposity, and glucose homeostasis.
In animal studies, genetic osteocalcin deficiency has been associated with decreased pancreatic b cell proliferation, with decreased insulin production and hyperglycemia, and decreased adiponectin expression in adipose tissue (1) . These metabolic alterations are reversed by the administration of exogenous osteocalcin, which increases insulin expression in pancreatic b cells (5) . Data collected in human studies seem to confirm that there is interplay between osteocalcin and insulin secretion and sensitivity. Several epidemiologic studies have shown decreased concentrations of serum osteocalcin in patients with type 2 diabetes (6, 7) or the metabolic syndrome (8, 9) . Similarly, serum osteocalcin concentrations have been negatively associated with fasting plasma glucose, fasting insulin, and HOMA-IR (10) (11) (12) . Moreover, most, but not all of the studies have reported an increase in osteocalcin with improved glycemic control in type 2 diabetic subjects (13) (14) (15) . However, to our knowledge, few longitudinal studies have evaluated the associations of total osteocalcin and ucOC 4 with changes in fasting glucose, insulin resistance, or altered b cell function.
The primary purpose of this study was to examine crosssectional and longitudinal associations between total and ucOC concentrations and measures of insulin resistance in elderly subjects at high cardiovascular disease risk.
SUBJECTS AND METHODS

Study subjects
The participants in this study were 79 community-dwelling men aged 55-80 y who were randomly selected from one of the PREDIMED centers (PREDIMED-Reus). The PREDIMED study is a large, parallel-group, randomized controlled trial that aims to assess the effect of the MeDiet on the primary prevention of cardiovascular disease. Participants were randomly assigned to 3 interventions: VOO diet, MeDiet with mixed nuts, or low-fat diet (control). The MeDiet groups received intensive education about following the MeDiet, and the VOO and mixed nuts were provided free of charge. Participants in the control group were given advice to follow a low-fat diet. Full details of the PREDIMED protocol were published elsewhere (16, 17) .
Candidates for the current study were free of cardiovascular heart disease but had 3 cardiovascular disease risk factors, namely, hypertension, dyslipidemia, overweight [BMI (in kg/m 2 ) 25], and family history of premature cardiovascular disease. Current smokers were excluded. Other exclusion criteria were severe chronic illness; alcohol or drug abuse; BMI . 40; .5% loss in body weight in the past year; medication use known to affect bone or calcium metabolism, such as corticosteroids, bisphosphonates, thiazides, and vitamin or mineral supplements; hormone replacement therapy; or use of large amounts of aspirin, anticoagulants, or medications that would interfere with vitamin K absorption. The local institutional review board approved the study protocol, and all participants provided written informed consent.
Procedures
At baseline and each annual visit, a short-questionnaire about lifestyle variables, medical conditions, and medication use were obtained. Usual dietary intakes were assessed throughout the study by using a previously validated, semiquantitative, 137-item food-frequency questionnaire (18) . Energy and nutrient intakes were calculated from Spanish food-composition tables (19) . A trained dietitian administered a 14-item questionnaire specifically designed to assess adherence to the traditional MeDiet. We assigned values of 0 or 1 to each item; a score of 14 points indicated maximum adherence to MeDiet. Physical activity was evaluated by using the validated Spanish version of the Minnesota Leisure Time Physical Activity Questionnaire (20) .
Biochemical analyses
Biochemical measurements were performed on blood samples collected after the subjects had fasted overnight. Serum concentrations of fasting glucose, total cholesterol, HDL cholesterol, and triglycerides were measured by using a routine laboratory biochemistry autoanalyzer. LDL-cholesterol concentrations were calculated by using Friedewald's formula (21) . Fasting insulin was measured by chemiluminescent immunoassay (Linco Research; intra-and interassay CVs: 6% and 10%, respectively). Insulin resistance was estimated on the basis of HOMA-IR; higher HOMA-IR values indicated higher insulin resistance. Altered b cell function was determined on the basis of HOMA-BCF, as described previously (DR Matthews, unpublished observations, 1985), which indicated that a higher HOMA-BCF value was related to a more favorable response. Serum total and ucOC concentrations were measured by electrochemiluminescence immunoassay (ROCHE; intra-and interassay CVs: 3.6% and 6.6%, respectively).
Statistical analyses
Mean (6 SE) values or percentages were used to describe the participants' baseline characteristics. Chi-square tests and onefactor ANOVA were used to compare the qualitative traits and means of quantitative variables, respectively, in subjects taking OADs or not taking OADs (NOAD group). Insulin concentrations, markers of insulin resistance and osteocalcin concentrations were logarithmically transformed to reduce skewness and the geometric mean and 95% CI were used to describe these variables. Repeated-measures ANOVA was used to explore differences of anthropometric and biochemical variables between baseline and after 2 y of follow-up. The Spearman correlation coefficients were calculated to assess the strength of the correlations of osteocalcin forms and lipid profile. Changes in osteocalcin forms across the intervention groups during the follow-up were compared by using the Kruskal-Wallis test. Mean differences in glucose and insulin metabolic markers during the follow-up were normally distributed. Linear regression models were fitted to explore how baseline concentrations of total osteocalcin and ucOC were associated with fasting glucose, fasting insulin, and insulin resistance after 2 y of follow up. Linear regression models were also fitted to explore how changes in total osteocalcin and ucOC were associated with changes in fasting glucose, fasting insulin, and insulin resistance measurements. Interaction tests for age (product-terms, age · osteocalcin, age · ucOC) showed no statistically significant differences in the association between osteocalcin and glucose or insulin metabolism. It is well known that OAD have an influence on circulating fasting insulin concentrations. Given these contrasting effects, we analyzed the effect of antidiabetic drugs on insulin sensitivity and secretion in our study population (see supplemental Table 1 under "Supplemental data" in the online issue). Because type 2 diabetic subjects taking OADs showed significant differences in insulin sensitivity and secretion compared with nondiabetic subjects or those not taking OAD, we analyzed the population as a whole but also studied patients according to their antidiabetic treatment separately. The analyses were performed by using SPSS software version 17.0 (SPSS Inc).
RESULTS
The clinical characteristics of the whole population and those taking or not taking OADs at baseline and after 2 y of follow up are shown in Table 1 . The study subjects were elderly, overweight, or obese and had several cardiovascular disease risk factors. No significant differences in age or adiposity indexes (eg, BMI and waist circumference) between subjects taking or not taking OADs were observed. Fasting glucose concentrations were significantly higher in the OAD group, whereas fasting insulin, HOMA-BCF, and total and LDL-cholesterol concentrations were higher in the NOAD group. Serum total osteocalcin or ucOC concentrations did not differ significantly between groups. In the entire group of participants and in those taking OADs, the correlation analysis showed that serum ucOC was positively related to triglycerides (r = 0.322 and r = 0.529, respectively; P , 0.05). However, no significant correlations were found between osteocalcin or ucOC and
TABLE 1
Anthropometric and biochemical measurements at baseline and changes after 2-y of follow-up A chi-square test was used to compare the qualitative traits between the NOAD and OAD groups. ANOVA was used to explore the differences between the NOAD and OAD groups. Repeated-measures ANOVA adjusted by intervention group was used to explore differences between baseline values and those after 2 y of follow-up. Represents the significance of changes in variables between the NOAD and OAD groups.
3
Represents the significance of changes in variables between baseline and after 2 y of follow-up. OSTEOCALCIN AND INSULIN METABOLISM total cholesterol, HDL, or LDL cholesterol. A significant decrease in total cholesterol and LDL cholesterol was observed in total subjects and in those subjects not taking OADs, whereas a decrease in HDL cholesterol was observed in the OAD group. However, no significant differences in the change in lipid profiles were observed between the OAD and NOAD groups after 2 y of follow-up (data not shown). In a correlation analysis at baseline, adherence to the MeDiet was not associated with osteocalcin or ucOC, neither in the total subjects (r = 0.068, P = 0.553; r = 20.012, P = 0.928) nor in the NOAD (r = 0.117, P = 0.392; r = 0.170, P = 0.269) or OAD (r = 20.095, P = 0.665; r = 20.361, P = 0.141) group. Moreover, no significant differences in changes in osteocalcin or ucOC were found after 2 y of follow-up between the intervention groups (data not shown).
No significant associations were observed between baseline serum total osteocalcin, ucOC, or %ucOC/osteocalcin concentrations and markers of insulin secretion after 2 y of follow-up in the whole population ( Table 2) . However, when OAD and NOAD subjects were studied separately, the baseline osteocalcin concentrations in the NOAD group were positively associated with higher concentrations of fasting insulin, HOMA-IR, and HOMA-BCF after 2 y of follow-up, even after adjustment for BMI, physical activity, use of statins, intervention group, and the baseline concentrations of each dependent variable. In the NOAD group, no significant associations were observed between serum ucOC concentrations and markers of insulin secretion or sensitivity, even after adjustment for potential confounders. No associations were observed between baseline serum osteocalcin or serum ucOC and fasting glucose, fasting insulin, HOMA-IR, or HOMA-BCF in those subjects taking OADs (Table 2) . In a multivariable linear regression analysis, both in the whole population and in the NOAD group by itself, changes in serum total osteocalcin were significantly associated with an increase in HOMA-BCF and changes in ucOC were associated with a decrease in HOMA-IR (Table 3 ) after 2 y of follow-up. No significant associations with glucose, insulin resistance, or b cell function were observed in the OAD group.
DISCUSSION
To the best of our knowledge, the current study was the first longitudinal study to evaluate the association between changes in serum osteocalcin and ucOC concentrations with the improvement in glucose metabolism, insulin resistance, and b cell dysfunction. Our results showed an increase in serum osteocalcin concentrations in association with increased b cell function, whereas an increase in serum ucOC concentrations was associated with an improvement in insulin action in elderly men. These findings support the hypothesis that circulating osteocalcin forms have beneficial effects on serum glucose and insulin sensitivity.
Osteocalcin is synthesized exclusively in cells of the mesenchymal osteoblast lineage, predominantly in bone. Small amounts circulate in blood and are considered to be a marker of bone formation (22) . Posttranslational carboxylation of osteocalcin occurs through vitamin K-dependent carboxylase activity, and both carboxylated and undercarboxylated forms are found in serum. In TABLE 3 Association between changes in osteocalcin and ucOC with changes in biomarkers of glucose metabolism after 2 y of follow-up 1 Changes in total osteocalcin (ng/mL) Changes in ucOC (ng/mL) addition to their role in bone metabolism, osteocalcin forms have been shown to be involved in glucose homeostasis. Lee et al (1) observed that mice lacking osteocalcin had lower b cell proliferation, glucose intolerance, and insulin resistance than did wild-type mice. Additionally, osteocalcin knockout mice had reduced serum adiponectin, which suggests a potential role for osteocalcin in insulin sensitivity and in insulin secretion. Moreover, in cell-based assays using isolated pancreatic islets, a b cell line and primary adipocytes, incubation with recombinant ucOC was sufficient to increase insulin secretion and b cell proliferation, which suggests that osteocalcin may be of value in the treatment of metabolic disorders. In contrast, carboxylated osteocalcin was found to have none of these effects (5) . Thus, only the undercarboxylated form of osteocalcin seems to have the ability to increase insulin secretion by pancreatic b cells and, by up-regulating adiponectin, to increase insulin sensitivity in mouse adipocytes. However, it is currently unclear which of the forms of osteocalcin is associated with insulin secretion or sensitivity in humans. Several epidemiologic studies have shown that serum osteocalcin concentrations are negatively associated with BMI, fat mass, fasting glucose, insulin concentrations, and insulin resistance as determined on the basis of HOMA-IR. Moreover, type 1 and type 2 diabetes have also been associated with lower concentrations of total osteocalcin (7, 11) . On the other hand, other studies have reported that ucOC is also negatively related to fasting glucose and insulin resistance as determined on the basis of HOMA-IR (14, 23) .
Many longitudinal studies linking osteocalcin and glucose metabolism were designed with the hypothesis that changes in glucose metabolism affect the bone. Therefore, improved glycemic control was associated with an increase in serum osteocalcin concentrations in diabetic subjects (7, 13, 15) . The results of the current longitudinal study support these findings. For the first time, as far as we know, they suggest that an increase in the serum total osteocalcin concentration is associated with an increase in HOMA-BCF, even after adjustment for confounding variables. At the same time, an increase in serum ucOC concentrations was negatively associated with insulin resistance as determined on the basis of HOMA-IR. These associations were stronger when the OAD group was excluded from the analysis. Our findings indicate that both osteocalcin forms are related to insulin secretion and sensitivity in humans. Additionally, we observed a positive relation between ucOC and triglycerides; however, because half of the subjects were taking lipid-lowering drugs, the relation between osteocalcin and the lipid profile cannot be explored.
Because vitamin K is a cofactor required for carboxylation of osteocalcin, dietary factors could play an important role in osteocalcin synthesis. However, our results do not support any effect of the MeDiet on serum osteocalcin or ucOC. Further studies are needed to determine whether specific dietary compounds affect the synthesis of osteocalcin and ucOC.
This interpretation of our results, however, should be treated with caution. Although the outcomes of our longitudinal analysis suggest that an increase in osteocalcin and ucOC protects against insulin resistance, they are based on a secondary analysis from a clinical trial designed to test a different hypothesis. In addition, our study subjects were elderly men at high risk of cardiovascular disease, so the generalizability of our findings could be limited. Finally, our sample size was relatively small, thus limiting the statistical power of some analyses. Balanced against these limitations is the fact that this is the longest longitudinal assessment of the association between changes in both osteocalcin forms and insulin secretion and sensitivity in humans.
In summary, the increase in total and ucOC was longitudinally associated with an improvement in insulin secretion and or sensitivity, which supports a direct link between bone and carbohydrate metabolism in elderly men.
